Pier 88 Investment Partners LLC Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Pier 88 Investment Partners LLC boosted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 187.2% in the second quarter, HoldingsChannel.com reports. The fund owned 3,360 shares of the company’s stock after purchasing an additional 2,190 shares during the period. Pier 88 Investment Partners LLC’s holdings in Krystal Biotech were worth $617,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of KRYS. EFG Asset Management North America Corp. lifted its position in shares of Krystal Biotech by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after purchasing an additional 60 shares in the last quarter. GAMMA Investing LLC increased its stake in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after buying an additional 94 shares in the last quarter. Arizona State Retirement System boosted its position in Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after buying an additional 108 shares during the period. Finally, Fiera Capital Corp grew its stake in shares of Krystal Biotech by 0.8% in the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after acquiring an additional 130 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 14.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Evercore ISI increased their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. Chardan Capital lifted their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Citigroup restated a “neutral” rating and set a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Finally, HC Wainwright raised their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $194.75.

Krystal Biotech Price Performance

Shares of KRYS opened at $184.19 on Friday. Krystal Biotech, Inc. has a 1-year low of $93.95 and a 1-year high of $219.34. The stock has a market cap of $5.26 billion, a PE ratio of 98.50 and a beta of 0.82. The firm has a fifty day moving average price of $194.65 and a 200 day moving average price of $176.47.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The firm had revenue of $70.28 million during the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business’s revenue was up 70283900.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.25) EPS. As a group, equities analysts expect that Krystal Biotech, Inc. will post 3.13 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).